WO2025125290 - NOVEL PHOSPHOGLICERATE DEHYDROGENASE INHIBITORS FOR THE TREATMENT OF FIBROSIS
National phase entry is expected:
Publication Number
WO/2025/125290
Publication Date
19.06.2025
International Application No.
PCT/EP2024/085607
International Filing Date
11.12.2024
Title **
[English]
NOVEL PHOSPHOGLICERATE DEHYDROGENASE INHIBITORS FOR THE TREATMENT OF FIBROSIS
[French]
NOUVEAUX INHIBITEURS DE PHOSPHOGLYCÉRATE DÉSHYDROGÉNASE POUR LE TRAITEMENT DE LA FIBROSE
Applicants **
CHIESI FARMACEUTICI S.P.A.
Inventors
ROŠČIĆ, Maja
KOŠTRUN, Sanja
Priority Data
23216180.2
13.12.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2465 | |
| EPO | Filing, Examination, Granting | 10250 | |
| Japan | Filing, Examination, Granting | 2204 | |
| South Korea | Filing, Examination, Granting | 2112 | |
| USA | Filing, Examination, Granting | 8940 |
Total:
25,971
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention generally relates to compounds of general formula (I) inhibiting 3-phosphoglycerate dehydrogenase (hereinafter PHGDH) receptor; the invention relates to compounds, including pharmaceutically acceptable salts thereof, and their use for the prevention and/or treatment of fibrosis, in particular idiopathic pulmonary fibrosis (IPF), as sole agent or in combinations with other active ingredients, as well as to the use of pharmaceutical compositions and combinations comprising said compounds.[French]
La présente invention concerne de manière générale des composés de formule générale (I) inhibant le récepteur de la 3-phosphoglycérate déshydrogénase (ci-après PHGDH) ; l'invention concerne des composés, des sels pharmaceutiquement acceptables de ceux-ci, et leur utilisation pour la prévention et/ou le traitement de la fibrose, en particulier de la fibrose pulmonaire idiopathique (FPI), en tant qu'agent unique ou en combinaisons avec d'autres principes actifs, ainsi que l'utilisation de compositions pharmaceutiques et de combinaisons comprenant lesdits composés.